美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床效果观察

Observation on clinical effect of metoprolol combined with trimetazidine in the treatment of coronary heart disease and heart failure

目的观察美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床效果。方法300例冠心病心力衰竭患者,根据随机数字表法分为传统组及联合治疗组,各150例。传统组行传统治疗,联合治疗组在传统组治疗基础上应用美托洛尔联合曲美他嗪进行治疗。比较两组临床治疗效果,治疗前后左心室收缩、舒张末期内径以及左心室射血分数。结果治疗后,联合治疗组治疗总有效率显著高于传统组,差异具有统计学意义(χ~2=27.119, P<0.05);治疗后,联合治疗组左心室收缩末期内径(30.14±2.31)mm、左心室舒张末期内径(50.31±3.69)mm显著小于传统组的(38.17±3.49)、(56.89±4.63)mm,差异均有统计学意义(t=23.499、13.612, P=0.001、0.001<0.05);治疗后,联合治疗组左心室射血分数(53.29±4.38)%高于传统组的(46.97±3.67)%,差异具有统计学意义(t=13.546, P=0.001<0.05)。结论在冠心病心力衰竭患者的临床治疗中,应用美托洛尔联合曲美他嗪进行治疗可有效提高临床治疗有效率,改善患者心脏功能,可在此类病患的治疗中积极推广应用。

Objective To observe the clinical effect of metoprolol combined with trimetazidine in the treatment of coronary heart disease and heart failure. Methods A total of 300 patients with coronary heart disease and heart failure were divided into traditional group and combined group according to random number table method, with 150 cases in each group. The traditional group received traditional therapy for treatment, and the combined group received metoprolol combined with trimetazidine for treatment. Comparison was made on clinical therapeutic effect, left ventricular end systolic diameter, left ventricular end diastolic diameter and left ventricular ejection fraction before and after treatment between the two groups. Results After treatment, the total effective rate in the combined group was significantly higher than that in the traditional group, and the difference was statistically significant(χ^2=27.119, P<0.05). After treatment, the left ventricular end systolic diameter(30.14±2.31) mm and left ventricular end diastolic diameter in the combined group was significantly smaller than(38.17±3.49) and(56.89±4.63) mm in traditional group. Their difference was statistically significant(t=23.499, 13.612;P=0.001, 0.001<0.05). After treatment, the left ventricular ejection fraction(53.29±4.38)% in combined group was higher than(46.97±3.67)% in traditional group, and the difference was statistically significant(t=13.546, P=0.001<0.05). Conclusion In the clinical treatment of patients with coronary heart disease and heart failure, metoprolol combined with trimetazidine can effectively improve the efficiency of clinical treatment, improve the cardiac function of patients. So it can be actively promoted in the treatment of such patients.